Evidence map›Paper›PMID 41097338›Full record

ArticleMolecules (Basel, Switzerland)2025

Structural Basis for D3/D4-Selective Antagonism of Piperazinylalkyl Pyrazole/Isoxazole Analogs.

Kwang-Eun Choi, Seong Hun Jang, Woo-Kyu Park, Kyoung Tai No, Hun Yeong Koh, Ae Nim Pae, Nam-Chul Cho

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kwang-Eun ChoiDrug Information Platform Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
Seong Hun JangR&D Center, PharmCADD, Busan 331, Republic of Korea.ORCID 0000-0003-0595-6506
Woo-Kyu ParkDivision of Drug Discovery Research, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
Kyoung Tai NoDepartment of Integrative Biotechnology, Yonsei University, Seoul 120749, Republic of Korea.ORCID 0000-0003-3187-8193
Hun Yeong KohDepartment of Chemistry, Inha University, Nam-gu, Incheon 402751, Republic of Korea.
Ae Nim PaeCenter of Brain Disorders, Brain Science Institute, Korea Institute of Science & Technology, Seoul 02792, Republic of Korea.
Nam-Chul ChoDrug Information Platform Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.

Funding

Korea Research Institute of Chemical Technology KK2551-20National Research Foundation of Korea RS-2021-NR057629National Research Foundation of Korea RS-2022-NR068434
6 · The paper itself

Abstract

Dopamine D2-like receptors, including D2, D3, and D4, are members of the aminergic G protein-coupled receptor (GPCR) family and are targets for neurological disorders. The development of subtype selective ligands is important for enhanced therapeutics and reduced side effects; however, it is challenging to design and develop selective ligands owing to the high degree of sequence homology among D2-like subtypes. To gain insight into the structural basis of subtype selectivity of piperazinylalkyl pyrazole/isoxazole analogs for D2-like dopamine receptors, we carried out 3D quantitative structure-activity relationship (3D-QSAR) and molecular docking studies. The 3D-QSAR models for the D2, D3, and D4 subtypes showed robust correlation coefficients (r

Indexed as

PiperazinesPyrazolesReceptors, Dopamine D3Receptors, Dopamine D4HumansLigandsMolecular Docking SimulationProtein BindingQuantitative Structure-Activity RelationshipReceptors, Dopamine D2LigandsPiperazinesPyrazolesReceptors, Dopamine D2Receptors, Dopamine D3Receptors, Dopamine D43D-QSARD2-like dopamine receptorspiperazinylalkyl pyrazole/isoxazole analogssubtype selectivity

Identifiers

PMID41097338
PMCPMC12526434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.